Moderna announced that its experimental mRNA flu vaccine, mRNA-1010, showed a stronger immune response than a standard flu shot in a late-stage trial. This success paves the way for the company to resubmit its application for a combination Covid-19 and flu vaccine, and file for approval of the standalone flu shot later this year. The trial involved over 40,000 adults, with Moderna's vaccine proving 26.6% more effective overall and 27.4% more effective in those 65 and older. Moderna aims to gain approvals for both vaccines next year, anticipating significant market share in the multi-billion dollar flu and Covid vaccine markets. The company's stock rose following the announcement.

Prepared by Olivia Bennett and reviewed by editorial team.